Literature DB >> 20407431

Plasma cytokine profiles in females with irritable bowel syndrome and extra-intestinal co-morbidity.

Paul Scully1, Declan P McKernan, John Keohane, David Groeger, Fergus Shanahan, Timothy G Dinan, Eamonn M M Quigley.   

Abstract

OBJECTIVES: Irritable bowel syndrome (IBS) is a functional disorder that is associated with a number of extra-intestinal co-morbidities and a pro-inflammatory profile. This study was designed to examine the cytokine profile among a group of IBS patients with the extra-intestinal co-morbidities fibromyalgia, premenstrual dysmorphic disorder, and chronic fatigue syndrome.
METHODS: In all, 100 female IBS patients with these co-morbidities, 21 IBS subjects without co-morbidity ("pure" IBS; Rome II), and 54 age-matched female controls took part in the study. Blood was drawn for measurement of the plasma cytokines interleukin (IL)-1β, IL-6, IL-8, IL-10, IL-12p70, IL-13, tumor necrosis factor (TNF)α, and interferon γ. The presence of the selected extra-intestinal manifestations was assessed using standard international criteria.
RESULTS: Patients with IBS have increased plasma levels of IL-6 and IL-8; those with these extra-intestinal co-morbidities were found to have, in addition, increased levels of IL-1β and TNFα. No associations were evident between cytokine profiles and the nature of the co-morbidity or number of extra-intestinal co-morbidities present.
CONCLUSIONS: Although IBS is characterized by a pro-inflammatory profile featuring the pro-inflammatory cytokines IL-6 and IL-8, IBS patients with certain extra-intestinal co-morbid conditions are distinguished by additional elevations in IL-1β and TNFα.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20407431     DOI: 10.1038/ajg.2010.159

Source DB:  PubMed          Journal:  Am J Gastroenterol        ISSN: 0002-9270            Impact factor:   10.864


  54 in total

1.  Probiotic treatment induced change of inflammation related metabolites in IBS-D patients/double-blind, randomized, placebo-controlled trial.

Authors:  Jinjoo Kim; Kumsun Cho; Joo Sung Kim; Hyun Chae Jung; Bumsik Kim; Myeong Soo Park; Geun Eog Ji; Joo-Youn Cho; Kyoung Sup Hong
Journal:  Food Sci Biotechnol       Date:  2019-12-23       Impact factor: 2.391

Review 2.  What does irritable bowel syndrome share with non-alcoholic fatty liver disease?

Authors:  Antonella Scalera; Matteo Nicola Dario Di Minno; Giovanni Tarantino
Journal:  World J Gastroenterol       Date:  2013-09-07       Impact factor: 5.742

3.  Cytokine-induced alterations of gastrointestinal motility in gastrointestinal disorders.

Authors:  Hirotada Akiho; Eikichi Ihara; Yasuaki Motomura; Kazuhiko Nakamura
Journal:  World J Gastrointest Pathophysiol       Date:  2011-10-15

4.  Global Cytokine Profiles and Association With Clinical Characteristics in Patients With Irritable Bowel Syndrome.

Authors:  Sean M P Bennet; Annikka Polster; Hans Törnblom; Stefan Isaksson; Sandrine Capronnier; Aurore Tessier; Boris Le Nevé; Magnus Simrén; Lena Öhman
Journal:  Am J Gastroenterol       Date:  2016-06-07       Impact factor: 10.864

Review 5.  Association of interleukin-10 polymorphisms with risk of irritable bowel syndrome: a meta-analysis.

Authors:  Shan-Yu Qin; Hai-Xing Jiang; Dong-Hong Lu; You Zhou
Journal:  World J Gastroenterol       Date:  2013-12-28       Impact factor: 5.742

Review 6.  Crosstalk at the mucosal border: importance of the gut microenvironment in IBS.

Authors:  Lena Öhman; Hans Törnblom; Magnus Simrén
Journal:  Nat Rev Gastroenterol Hepatol       Date:  2014-12-02       Impact factor: 46.802

7.  Associations among gut permeability, inflammatory markers, and symptoms in patients with irritable bowel syndrome.

Authors:  Robert J Shulman; Monica E Jarrett; Kevin C Cain; Elizabeth K Broussard; Margaret M Heitkemper
Journal:  J Gastroenterol       Date:  2014-01-17       Impact factor: 7.527

Review 8.  Probiotics, fibre and herbal medicinal products for functional and inflammatory bowel disorders.

Authors:  Diego Currò; Gianluca Ianiro; Silvia Pecere; Stefano Bibbò; Giovanni Cammarota
Journal:  Br J Pharmacol       Date:  2016-10-25       Impact factor: 8.739

9.  Gut inflammation in chronic fatigue syndrome.

Authors:  Shaheen E Lakhan; Annette Kirchgessner
Journal:  Nutr Metab (Lond)       Date:  2010-10-12       Impact factor: 4.169

Review 10.  Complementary and alternative medicines in irritable bowel syndrome: an integrative view.

Authors:  Oliver Grundmann; Saunjoo L Yoon
Journal:  World J Gastroenterol       Date:  2014-01-14       Impact factor: 5.742

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.